{"gene":"G0S2","run_date":"2026-06-09T23:54:44","timeline":{"discoveries":[{"year":2009,"finding":"G0S2 encodes a mitochondria-localized protein that directly binds Bcl-2 and promotes apoptosis by preventing the formation of protective Bcl-2/Bax heterodimers; G0S2 lacks Bcl-2 homology domains but antagonizes Bcl-2 antiapoptotic activity. Expression is induced by TNF-alpha through NF-κB.","method":"Co-immunoprecipitation, subcellular fractionation, ectopic expression in cancer cell lines, expression profiling with NF-κB inhibition","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP demonstrating Bcl-2 binding, subcellular fractionation for localization, functional apoptosis assays; single lab, multiple orthogonal methods","pmids":["19706769"],"is_preprint":false},{"year":2010,"finding":"G0S2 acts as a direct inhibitor of adipose triglyceride lipase (ATGL) activity and ATGL-mediated lipolysis. G0S2 binds ATGL independently of ATGL's activity state or the presence of CGI-58. Combined expression of CGI-58 and ATGL cannot stimulate lipid droplet turnover in G0S2-expressing cells, indicating G0S2 and CGI-58 regulate ATGL via non-competing mechanisms.","method":"Co-immunoprecipitation, lipid droplet morphology assays, lipolysis assays in cells overexpressing G0S2, CGI-58 and ATGL constructs","journal":"Cell cycle (Georgetown, Tex.)","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct binding demonstrated by Co-IP, functional lipolysis assays, replicated across multiple subsequent studies from independent labs","pmids":["20676045"],"is_preprint":false},{"year":2011,"finding":"The minimal active domain of ATGL required for inhibition by G0S2 ranges from amino acids Ile10 to Leu254. This minimal fragment retains both protein-protein interaction with G0S2 and susceptibility to G0S2-mediated inhibition, implying G0S2 interacts with the patatin-domain region of ATGL.","method":"Truncation mutagenesis, in vitro lipase activity assays, protein-protein interaction assays, 3D homology modeling","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro lipase activity assays with defined truncation mutants plus structural homology modeling; single lab but multiple orthogonal biochemical methods","pmids":["22039468"],"is_preprint":false},{"year":2008,"finding":"G0S2 is a direct transcriptional target of retinoic acid (RA) signaling. Retinoic acid response element (RARE) half-sites in the G0S2 promoter are required for RA-mediated transcriptional activation; mutation of these sites blocks activation. RAR co-transfection assays confirmed transcriptional activation after RA treatment. G0S2 protein is rapidly induced in APL cells and APL transgenic mice treated with RA in an RAR-dependent manner.","method":"Reporter gene assays with RARE site mutagenesis, RAR co-transfection, actinomycin D/cycloheximide treatment, RT-PCR, polyclonal antibody detection of protein","journal":"International journal of oncology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — promoter reporter assays with site-directed mutagenesis of RARE sites, confirmed at protein level; single lab but multiple orthogonal methods","pmids":["18636162"],"is_preprint":false},{"year":2012,"finding":"G0S2 localizes to mitochondria, endoplasmic reticulum, and early endosomes in hematopoietic cells. The hydrophobic domain of G0S2 interacts with the RGG-repeat domain of nucleolin, retaining nucleolin in the cytosol; this cytosolic retention of nucleolin occurs in resting but not proliferating hematopoietic stem cells. G0S2 overexpression increases HSC quiescence while G0S2 knockdown promotes HSC division.","method":"Retroviral overexpression, shRNA knockdown, bone marrow transplantation, cell cycle analysis, proteomic identification of binding partners (nucleolin), subcellular fractionation/imaging","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain- and loss-of-function in primary HSCs with defined phenotype (quiescence), proteomic identification of nucleolin interaction, localization data; single lab","pmids":["22693613"],"is_preprint":false},{"year":2013,"finding":"G0S2 inhibits proliferation of K562 leukemia cells by sequestering nucleolin in the cytosol, preventing its pro-proliferative functions in the nucleolus. Knockdown of G0S2 by shRNA in 5-azacytidine-treated K562 cells restores proliferation.","method":"5-azacytidine demethylation, shRNA knockdown, xenograft models, co-immunoprecipitation/interaction assays with nucleolin, proliferation assays","journal":"Leukemia research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function rescue experiment, binding to nucleolin demonstrated, in vivo xenograft; single lab","pmids":["24183236"],"is_preprint":false},{"year":2013,"finding":"Adipose-specific overexpression of G0S2 in transgenic mice inhibits basal and adrenergically stimulated lipolysis in adipose explants, reduces in vivo lipolysis and ketogenesis during fasting, impairs the metabolic shift from carbohydrates to fatty acids, and promotes lipid droplet accumulation in brown adipocytes with defective cold adaptation.","method":"Adipose-specific transgenic mouse model, lipolysis assays in adipose explants, in vivo metabolic measurements, β3-adrenergic agonist injection, cold tolerance tests, high-fat diet feeding","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo genetic model with multiple metabolic phenotype readouts including direct lipolysis assays; rigorous transgenic mouse study","pmids":["24302733"],"is_preprint":false},{"year":2014,"finding":"Deletion of G0s2 in mice leads to a lean phenotype with enhanced adipose lipase activity, increased stimulated lipolysis in adipocytes, resistance to high-fat diet weight gain, improved glucose and insulin tolerance, and enhanced 'browning' of white adipose tissue with upregulation of thermoregulatory genes.","method":"G0s2 knockout mouse generation, lipolysis assays, metabolic phenotyping (body composition, glucose/insulin tolerance tests, energy metabolism), gene expression analysis","journal":"Diabetologia","confidence":"High","confidence_rationale":"Tier 2 / Strong — complete knockout mouse with multiple orthogonal metabolic phenotype readouts; replicated by another lab (PMID 24556704)","pmids":["25381555"],"is_preprint":false},{"year":2014,"finding":"G0s2-null mice are lean with increased serum glycerol (indicating enhanced lipolysis), decreased gonadal fat pad weight, improved cold tolerance, and augmented thermogenic gene expression. G0S2 is most highly expressed in adipose tissue.","method":"G0s2 knockout mouse, body composition analysis, serum glycerol measurement, cold tolerance tests, tissue expression profiling","journal":"Cancer biology & therapy","confidence":"High","confidence_rationale":"Tier 2 / Strong — independent knockout mouse study replicating lean phenotype and lipolysis findings; corroborates PMID 25381555","pmids":["24556704"],"is_preprint":false},{"year":2016,"finding":"G0S2 protein is degraded via K48-linked polyubiquitination at lysine-25. Mutation of K25 abolishes ubiquitination and increases protein stability. G0S2 protein is stabilized by ATGL expression and by fatty acid-induced triglyceride accumulation through distinct mechanisms. G0S2 protein levels are reduced in adipose tissue of ATGL-deficient mice.","method":"Site-directed mutagenesis of K25, ubiquitination assays, proteasome inhibitor treatment, co-expression with ATGL, fatty acid treatment, ATGL-knockout mouse adipose tissue analysis","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct mutagenesis of ubiquitination site combined with biochemical ubiquitination assays and in vivo validation in ATGL-KO mice; multiple orthogonal methods","pmids":["27248498"],"is_preprint":false},{"year":2016,"finding":"G0S2 suppresses oncogene-induced transformation independently of ATGL inhibition. G0s2-null MEFs are readily transformed by HRAS or EGFR; restoration of G0S2 reverses HRAS-driven transformation. Gene expression analysis reveals upregulation of MYC target signatures in G0s2-null MEFs; RNAi or pharmacologic inhibition of MYC abrogates transformation.","method":"G0s2-null MEFs, oncogene transformation assays (HRAS, EGFR), G0S2 rescue expression, gene expression profiling, MYC RNAi and pharmacologic inhibition","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic null MEFs with rescue, epistasis via MYC inhibition; single lab with multiple methods","pmids":["26837760"],"is_preprint":false},{"year":2016,"finding":"During ATRA-induced APL differentiation, PML/RARα is recruited to the G0S2 promoter in an ATRA-dependent (ligand-dependent) manner and cooperates physically and functionally with C/EBPε (specifically the p30 isoform) to activate G0S2 transcription. ChIP-qPCR demonstrated co-occupancy of PML/RARα and C/EBPε at the G0S2 promoter.","method":"Chromatin immunoprecipitation (ChIP)-qPCR in NB4 and PR9 cell lines and primary APL cells, co-immunoprecipitation of PML/RARα and C/EBPε, ATRA treatment","journal":"Journal of leukocyte biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-qPCR in multiple cell types including primary cells, physical interaction demonstrated by Co-IP; single lab","pmids":["27605212"],"is_preprint":false},{"year":2019,"finding":"G0S2 possesses an intrinsic lysophosphatidic acid acyltransferase (LPAAT) enzymatic activity, directly catalyzing phosphatidic acid synthesis from lysophosphatidic acid and acyl-CoA. A distinct 4-amino acid motif is required for this LPAAT activity. Knockdown of G0S2 in ATGL-deficient mice still decreases hepatic TG content, and overexpression of G0S2 promotes fatty acid incorporation into TGs even in ATGL-deficient hepatocytes, demonstrating a lipolysis-independent TG synthesis function.","method":"In vitro LPAAT activity assay, deletion mutagenesis of 4-aa motif, overexpression/knockdown in ATGL-deficient mice and hepatocytes, isotopic fatty acid incorporation assays","journal":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro enzymatic assay for LPAAT activity plus mutagenesis of active motif, validated in vivo in ATGL-null mice; multiple orthogonal methods in single study","pmids":["30802154"],"is_preprint":false},{"year":2019,"finding":"G0S2 inhibits ATGL via non-competitive inhibition by interacting with ATGL's patatin domain. G0S2 inhibition of ATGL reduces lipid droplet turnover and, in glioma stem-like cells, attenuates RNF168-mediated 53BP1 ubiquitination through mTOR-S6K signaling activation and increased 53BP1 protein stability, thereby enhancing DNA repair and radioresistance.","method":"G0S2 knockdown/overexpression in GSCs, lipid droplet immunofluorescence, γ-H2AX foci assay, mTOR/S6K pathway analysis, 53BP1 ubiquitination assay, xenograft survival experiments","journal":"Journal of experimental & clinical cancer research : CR","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic gain/loss-of-function with mechanistic pathway readouts (mTOR-S6K-53BP1) and in vivo xenograft; single lab","pmids":["30953555"],"is_preprint":false},{"year":2020,"finding":"In zebrafish, G0s2 functions as a positive regulator of oxidative phosphorylation (OXPHOS) and maintains intra-mitochondrial ATP concentration under hypoxia. TALEN-mediated g0s2 knockout abolishes hypoxic tolerance in zebrafish hearts, while cardiomyocyte-specific overexpression confers strong ischemic tolerance. In vivo FRET-based ATP biosensor imaging showed that g0s2-expressing cardiomyocytes maintain ATP production and contractility during hypoxia.","method":"TALEN knockout zebrafish, cardiomyocyte-specific transgenic zebrafish, in vivo mitochondria-targeted FRET ATP biosensor imaging, mosaic overexpression model","journal":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vivo real-time ATP imaging with FRET biosensor, genetic loss- and gain-of-function, side-by-side cell comparison; multiple orthogonal methods","pmids":["31916304"],"is_preprint":false},{"year":2015,"finding":"G0S2 inhibits energy production by oxidative phosphorylation in naïve CD8+ T cells. G0S2-null naïve CD8+ T cells display increased basal and spare respiratory capacity associated with increased AMPK-α phosphorylation, not increased mitochondrial biogenesis. G0S2 expression in naïve T cells is suppressed downstream of TCR activation via MAPK, calcium/calmodulin, PI3K, and mTOR pathways.","method":"G0s2-null mice, Seahorse respirometry, mitochondrial biogenesis markers, AMPK phosphorylation analysis, T cell activation assays, in vivo lymphopenia-induced proliferation","journal":"Immunology and cell biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockout with Seahorse respirometry (direct mitochondrial function readout) and AMPK signaling analysis; single lab","pmids":["25666096"],"is_preprint":false},{"year":2022,"finding":"The minimal sequence of G0S2 required for ATGL inhibition spans amino acids 20–44, containing a hydrophobic region. Residues Y27, V28, G30, A34, G37, V39, and L42 play substantial roles in ATGL inhibition. N-terminal extensions (aa 20–27) facilitate non-specific interactions that increase binding to ATGL. Full-length G0S2 shows greater tolerance to single amino acid exchanges due to stronger contributions of these flanking interactions.","method":"Site-directed mutagenesis, truncation analysis, in vitro ATGL lipase activity assays, binding assays with G0S2 variants","journal":"Biochimica et biophysica acta. Molecular and cell biology of lipids","confidence":"High","confidence_rationale":"Tier 1 / Moderate — systematic site-directed mutagenesis and truncation validated by in vitro lipase activity assays; single lab but comprehensive per-residue mutagenesis","pmids":["35026402"],"is_preprint":false},{"year":2022,"finding":"ATGL-independent localization of G0S2 to both the endoplasmic reticulum (ER) and lipid droplets (LDs) is mediated by a hairpin structure consisting of two hydrophobic sequences. Positively charged residues in the hinge region of this hairpin sort G0S2 from ER to LDs. When ATGL is co-expressed, the role of these positive charges in LD sorting becomes dispensable.","method":"Structural prediction, cell imaging with fluorescent-tagged constructs, mutagenesis of hydrophobic sequences and charged residues, co-expression with ATGL","journal":"Journal of cell science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell imaging with mutant constructs identifying structural determinants; single lab, multiple mutants tested","pmids":["36420951"],"is_preprint":false},{"year":2014,"finding":"TNF-α reduces G0S2 expression in adipocytes through proteasomal degradation of PPARγ, which abolishes PPARγ binding to the G0S2 promoter. Proteasome inhibition (MG-132) maintains PPARγ levels and preserves G0S2 expression. Overexpression of G0S2 or PPARγ partially reverses TNF-α-induced lipolysis.","method":"3T3-L1 adipocyte differentiation, TNF-α treatment, proteasome inhibitor MG-132, ChIP assay for PPARγ binding to G0S2 promoter, G0S2 and PPARγ overexpression, lipolysis assays","journal":"Cytokine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP demonstrating PPARγ promoter binding, proteasome inhibitor rescue, functional lipolysis assay; single lab","pmids":["24993166"],"is_preprint":false},{"year":2023,"finding":"JAZF1 represses G0S2 transcription in human endometrial stromal cells (hESCs) by interacting with the G0S2 transcriptional activator Purβ, restricting its activity. JAZF1 depletion leads to increased G0S2 expression, apoptosis, and defective decidualization. G0S2 was identified as a key driver of hESC apoptosis in this context.","method":"JAZF1 siRNA/overexpression in hESCs, G0S2 promoter analysis, co-immunoprecipitation of JAZF1 with Purβ, decidualization assays, apoptosis assays, patient tissue analysis","journal":"Communications biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP of JAZF1-Purβ interaction with G0S2 promoter reporter assays and loss-of-function phenotype; single lab","pmids":["37244968"],"is_preprint":false},{"year":2025,"finding":"Genetic ablation of G0S2 in mice completely abolishes diet-induced hypertriglyceridemia and attenuates atherogenesis by enhancing whole-body triglyceride clearance. G0S2 deletion increases circulating LPL concentration and activity predominantly from white adipose tissue (WAT), and enhances LPL protein stability in adipocytes. This effect is reversed by ATGL inhibition, linking intracellular ATGL activity (regulated by G0S2) to extracellular LPL-mediated lipolysis. WAT transplantation from G0S2-deficient mice normalizes plasma TG levels in hypertriglyceridemic mice.","method":"G0S2 global knockout mice, WAT transplantation, LPL activity and concentration measurement, ATGL inhibitor treatment, dietary lipid challenge, atherosclerosis assessment","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo genetic ablation with WAT transplantation rescue, LPL activity measurements, ATGL inhibitor epistasis; multiple orthogonal approaches in single rigorous study","pmids":["40100923"],"is_preprint":false},{"year":2025,"finding":"In a mouse model of brain-evoked catabolism of all adipose depots, downregulation of G0s2 (along with Acvr1c and Npr3) is part of the cell-autonomous lipolytic inhibitor suppression that activates catecholamine-independent lipolysis, enabling mobilization of stable adipose stores including bone marrow adipose tissue. This process requires ATGL-dependent lipolysis.","method":"Genetic, surgical, and chemical intervention mouse models; adipose-specific gene expression analysis; G0s2 expression profiling during cachexia/starvation models","journal":"bioRxiv","confidence":"Low","confidence_rationale":"Tier 3 / Weak — G0s2 identified as one of several inhibitors downregulated in a complex model; specific mechanistic role of G0s2 not isolated; preprint","pmids":["bio_10.1101_2024.07.30.605812"],"is_preprint":true}],"current_model":"G0S2 is a small, mitochondria/ER/lipid-droplet-localized protein that functions as a potent endogenous non-competitive inhibitor of adipose triglyceride lipase (ATGL) by binding ATGL's patatin domain through a conserved hydrophobic region (residues 20–44), thereby suppressing intracellular lipolysis; it also possesses an intrinsic lysophosphatidic acid acyltransferase (LPAAT) activity promoting triglyceride synthesis; beyond lipid metabolism it antagonizes Bcl-2 antiapoptotic function by disrupting Bcl-2/Bax heterodimers, promotes cellular quiescence by sequestering nucleolin in the cytosol, positively regulates mitochondrial ATP production/oxidative phosphorylation, and is transcriptionally regulated by NF-κB (TNF-α), RARα/RARE elements (retinoic acid), PPARγ (via C/EBPβ), and the PML/RARα–C/EBPε complex in APL cells, while its own protein stability is controlled by K48-linked polyubiquitination at K25 and is stabilized by ATGL interaction and triglyceride accumulation."},"narrative":{"mechanistic_narrative":"G0S2 is a small, multi-localized regulatory protein whose dominant characterized role is the suppression of intracellular triglyceride lipolysis through direct, non-competitive inhibition of adipose triglyceride lipase (ATGL) [PMID:20676045, PMID:30953555]. G0S2 binds the patatin-domain region of ATGL independently of ATGL's activity state or the co-activator CGI-58, and this inhibition operates by a mechanism distinct from CGI-58-mediated activation [PMID:20676045, PMID:22039468]. The minimal inhibitory determinant is a hydrophobic region spanning residues 20–44, with specific residues (Y27, V28, G30, A34, G37, V39, L42) driving ATGL inhibition [PMID:35026402]; a hairpin of two hydrophobic sequences with charged hinge residues directs ATGL-independent sorting of G0S2 between the endoplasmic reticulum and lipid droplets [PMID:36420951]. In vivo, adipose-specific overexpression suppresses basal and stimulated lipolysis, ketogenesis, and the carbohydrate-to-fat metabolic shift [PMID:24302733], whereas G0s2 deletion produces a lean, lipolysis-enhanced phenotype with improved glucose tolerance and adipose browning [PMID:25381555, PMID:24556704], and abolishes diet-induced hypertriglyceridemia and atherogenesis by coupling intracellular ATGL activity to extracellular LPL-mediated triglyceride clearance [PMID:40100923]. Independent of lipolysis inhibition, G0S2 carries an intrinsic lysophosphatidic acid acyltransferase activity that promotes triglyceride synthesis [PMID:30802154]. Beyond lipid metabolism, G0S2 antagonizes Bcl-2 antiapoptotic function by disrupting Bcl-2/Bax heterodimers [PMID:19706769], enforces hematopoietic and leukemic cell quiescence by sequestering nucleolin in the cytosol via its hydrophobic domain [PMID:22693613, PMID:24183236], suppresses oncogene-induced transformation through a MYC-dependent mechanism [PMID:26837760], and regulates mitochondrial oxidative phosphorylation and ATP output [PMID:31916304, PMID:25666096]. G0S2 transcription is controlled by retinoic acid through RARE elements [PMID:18636162], by the PML/RARα–C/EBPε complex in APL cells [PMID:27605212], and by PPARγ, whose TNF-α-driven degradation lowers G0S2 [PMID:24993166], while G0S2 protein stability is set by K48-linked polyubiquitination at K25 and is stabilized by ATGL binding and triglyceride accumulation [PMID:27248498].","teleology":[{"year":2008,"claim":"Establishing how G0S2 is induced linked it to retinoic acid signaling, identifying the first defined transcriptional input.","evidence":"RARE-site reporter mutagenesis and RAR co-transfection in APL cells and transgenic mice","pmids":["18636162"],"confidence":"High","gaps":["Did not address G0S2 protein function downstream of induction","Other transcriptional inputs unexplored at this stage"]},{"year":2009,"claim":"The first functional assignment placed G0S2 at mitochondria as a pro-apoptotic antagonist of Bcl-2, establishing a non-metabolic role.","evidence":"Reciprocal Co-IP, subcellular fractionation, and apoptosis assays in cancer cell lines with NF-κB-inhibition expression profiling","pmids":["19706769"],"confidence":"Medium","gaps":["Structural basis of Bcl-2 binding without BH domains unresolved","Relationship to later lipid functions not addressed"]},{"year":2010,"claim":"Identification of G0S2 as a direct ATGL inhibitor defined its central metabolic function and distinguished it mechanistically from CGI-58.","evidence":"Co-IP and lipolysis/lipid droplet assays in cells co-expressing G0S2, CGI-58, and ATGL","pmids":["20676045"],"confidence":"High","gaps":["Inhibition mechanism (competitive vs non-competitive) not yet defined","Binding interface on ATGL not mapped"]},{"year":2011,"claim":"Mapping the ATGL fragment required for inhibition localized the G0S2 interaction to the patatin domain, advancing structural understanding of the inhibitory complex.","evidence":"Truncation mutagenesis, in vitro lipase assays, and 3D homology modeling","pmids":["22039468"],"confidence":"High","gaps":["G0S2 residues mediating contact not yet defined","No co-crystal structure"]},{"year":2012,"claim":"Discovery of nucleolin sequestration explained a lipolysis-independent role in enforcing hematopoietic stem cell quiescence.","evidence":"Retroviral overexpression/shRNA in primary HSCs, proteomic partner identification, fractionation/imaging","pmids":["22693613"],"confidence":"Medium","gaps":["How nucleolin retention links to cell-cycle machinery unclear","Single-lab finding"]},{"year":2013,"claim":"Extending the quiescence mechanism to leukemia showed G0S2 restrains proliferation by cytosolic nucleolin sequestration in K562 cells.","evidence":"5-azacytidine demethylation, shRNA rescue, nucleolin interaction assays, and xenografts","pmids":["24183236"],"confidence":"Medium","gaps":["Generality across leukemia subtypes untested","Quantitative contribution vs lipid roles unknown"]},{"year":2013,"claim":"An adipose-overexpression mouse confirmed in vivo that G0S2 suppresses lipolysis, ketogenesis, and fuel switching, validating its physiological lipase-inhibitory role.","evidence":"Adipose-specific transgenic mice with lipolysis assays, fasting metabolism, and cold-tolerance tests","pmids":["24302733"],"confidence":"High","gaps":["Endogenous regulation under physiological states not addressed by overexpression","Tissue-specific contributions beyond adipose unexamined"]},{"year":2014,"claim":"Loss-of-function mouse studies established the reciprocal phenotype, showing G0s2 deletion drives leanness, enhanced lipolysis, browning, and improved glucose handling.","evidence":"Two independent G0s2 knockout mouse lines with metabolic phenotyping and tissue expression profiling","pmids":["25381555","24556704"],"confidence":"High","gaps":["Mechanism of WAT browning downstream of G0S2 loss not dissected","Effects on non-adipose tissues underexplored"]},{"year":2014,"claim":"Linking TNF-α to PPARγ degradation explained how inflammatory signaling lowers G0S2 transcription and de-represses lipolysis.","evidence":"3T3-L1 adipocytes, ChIP for PPARγ promoter binding, MG-132 rescue, and lipolysis assays","pmids":["24993166"],"confidence":"Medium","gaps":["Direct PPARγ response element not finely mapped","Interplay with other transcriptional inputs unaddressed"]},{"year":2015,"claim":"Demonstrating that G0S2 restrains oxidative phosphorylation in naive CD8+ T cells extended its role to mitochondrial bioenergetics and immune cell metabolism.","evidence":"G0s2-null mice, Seahorse respirometry, AMPK phosphorylation, and TCR-pathway analysis","pmids":["25666096"],"confidence":"Medium","gaps":["Molecular target within OXPHOS machinery unidentified","Apparent opposite direction vs cardiac OXPHOS role unresolved"]},{"year":2016,"claim":"Defining K48-polyubiquitination at K25 and ATGL/triglyceride-dependent stabilization revealed how G0S2 protein abundance is post-translationally tuned.","evidence":"K25 mutagenesis, ubiquitination and proteasome assays, ATGL co-expression, and ATGL-KO adipose analysis","pmids":["27248498"],"confidence":"High","gaps":["Responsible E3 ligase not identified","Mechanism of triglyceride-induced stabilization unresolved"]},{"year":2016,"claim":"Showing tumor-suppressive activity independent of ATGL via MYC established a lipolysis-uncoupled function in oncogenic transformation.","evidence":"G0s2-null MEFs with HRAS/EGFR transformation assays, rescue, expression profiling, and MYC inhibition","pmids":["26837760"],"confidence":"Medium","gaps":["Direct molecular link between G0S2 and MYC signaling unknown","Relevance to human tumors not established here"]},{"year":2016,"claim":"Identifying ligand-dependent PML/RARα recruitment with C/EBPε to the G0S2 promoter explained how ATRA induces G0S2 during APL differentiation.","evidence":"ChIP-qPCR and Co-IP in NB4/PR9 and primary APL cells with ATRA treatment","pmids":["27605212"],"confidence":"Medium","gaps":["Functional consequence of induced G0S2 in differentiation not isolated","Single-lab finding"]},{"year":2019,"claim":"Discovery of intrinsic LPAAT activity revealed that G0S2 actively promotes triglyceride synthesis, a function entirely separate from lipolysis inhibition.","evidence":"In vitro LPAAT assays, 4-aa motif mutagenesis, and isotopic FA-incorporation in ATGL-deficient hepatocytes/mice","pmids":["30802154"],"confidence":"High","gaps":["Relative contribution of LPAAT vs ATGL-inhibitory function in vivo unclear","Structural basis of catalysis undefined"]},{"year":2019,"claim":"Defining non-competitive patatin-domain inhibition and connecting G0S2-driven lipid droplet accumulation to mTOR-S6K-53BP1 signaling linked it to DNA repair and radioresistance in glioma stem cells.","evidence":"Knockdown/overexpression in GSCs, lipid droplet imaging, γ-H2AX foci, 53BP1 ubiquitination assays, and xenografts","pmids":["30953555"],"confidence":"Medium","gaps":["Mechanistic chain from lipid droplets to mTOR not fully resolved","Generality beyond glioma untested"]},{"year":2020,"claim":"Zebrafish genetics established G0S2 as a positive regulator of OXPHOS and mitochondrial ATP under hypoxia, conferring ischemic tolerance.","evidence":"TALEN knockout and cardiomyocyte-specific transgenic zebrafish with in vivo FRET ATP biosensor imaging","pmids":["31916304"],"confidence":"High","gaps":["Direction opposite to T-cell OXPHOS finding unreconciled","Molecular interaction with OXPHOS machinery unknown"]},{"year":2022,"claim":"Per-residue mapping of the 20–44 hydrophobic region and identification of the ER/lipid-droplet sorting hairpin defined the structural determinants of inhibition and localization.","evidence":"Systematic mutagenesis with in vitro ATPL lipase assays and fluorescent-construct imaging of ER/LD sorting","pmids":["35026402","36420951"],"confidence":"High","gaps":["No high-resolution structure of the G0S2-ATGL complex","How ATGL overrides charge-dependent LD sorting unresolved"]},{"year":2023,"claim":"Identifying JAZF1 repression of G0S2 via the activator Purβ connected G0S2 to apoptosis control during endometrial decidualization.","evidence":"JAZF1 knockdown/overexpression, JAZF1-Purβ Co-IP, promoter analysis, and decidualization/apoptosis assays in hESCs","pmids":["37244968"],"confidence":"Medium","gaps":["Mechanism by which G0S2 drives hESC apoptosis here not detailed","Single tissue context"]},{"year":2025,"claim":"WAT transplantation and LPL epistasis showed that intracellular ATGL activity controlled by G0S2 governs extracellular LPL-mediated plasma triglyceride clearance and atherogenesis.","evidence":"G0S2 global KO mice, WAT transplantation rescue, LPL activity measurement, and ATGL inhibitor reversal under dietary lipid challenge","pmids":["40100923"],"confidence":"High","gaps":["Molecular link between intracellular lipolysis and LPL stability not defined","Human relevance of the WAT-LPL axis untested"]},{"year":null,"claim":"The unifying biochemical basis reconciling G0S2's opposing roles in OXPHOS, its non-lipid partners (Bcl-2, nucleolin), and its ATGL-independent functions remains undefined.","evidence":"","pmids":[],"confidence":"Low","gaps":["No structure of any G0S2 complex","Opposing OXPHOS phenotypes across systems unreconciled","E3 ligase for K25 ubiquitination unidentified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[1,2,13,16]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[12]}],"localization":[{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[0,4]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[4,17]},{"term_id":"GO:0005811","term_label":"lipid droplet","supporting_discovery_ids":[17]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[4,5]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[4]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[1,6,7,12,20]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[0]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[3,11,18]}],"complexes":[],"partners":["PNPLA2","BCL2","NCL"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P27469","full_name":"G0/G1 switch protein 2","aliases":["G0/G1 switch regulatory protein 2","Putative lymphocyte G0/G1 switch gene"],"length_aa":103,"mass_kda":11.3,"function":"Promotes apoptosis by binding to BCL2, hence preventing the formation of protective BCL2-BAX heterodimers","subcellular_location":"Mitochondrion","url":"https://www.uniprot.org/uniprotkb/P27469/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/G0S2","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1165,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/G0S2","total_profiled":1310},"omim":[{"mim_id":"614447","title":"G0/G1 SWITCH GENE 2; G0S2","url":"https://www.omim.org/entry/614447"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"adipose tissue","ntpm":755.3},{"tissue":"bone marrow","ntpm":1271.4}],"url":"https://www.proteinatlas.org/search/G0S2"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P27469","domains":[{"cath_id":"1.20.5","chopping":"19-98","consensus_level":"medium","plddt":80.8398,"start":19,"end":98}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P27469","model_url":"https://alphafold.ebi.ac.uk/files/AF-P27469-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P27469-F1-predicted_aligned_error_v6.png","plddt_mean":76.81},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=G0S2","jax_strain_url":"https://www.jax.org/strain/search?query=G0S2"},"sequence":{"accession":"P27469","fasta_url":"https://rest.uniprot.org/uniprotkb/P27469.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P27469/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P27469"}},"corpus_meta":[{"pmid":"19706769","id":"PMC_19706769","title":"Identification of a protein, G0S2, that lacks Bcl-2 homology domains and interacts with and antagonizes Bcl-2.","date":"2009","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/19706769","citation_count":114,"is_preprint":false},{"pmid":"23032787","id":"PMC_23032787","title":"The G0/G1 switch gene 2 (G0S2): regulating metabolism and beyond.","date":"2012","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/23032787","citation_count":105,"is_preprint":false},{"pmid":"20676045","id":"PMC_20676045","title":"Differential control of ATGL-mediated lipid droplet degradation by CGI-58 and G0S2.","date":"2010","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/20676045","citation_count":97,"is_preprint":false},{"pmid":"22039468","id":"PMC_22039468","title":"The minimal domain of adipose triglyceride lipase (ATGL) ranges until leucine 254 and can be activated and inhibited by CGI-58 and G0S2, respectively.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22039468","citation_count":77,"is_preprint":false},{"pmid":"21613358","id":"PMC_21613358","title":"Fasting, but not exercise, increases adipose triglyceride lipase (ATGL) protein and reduces G(0)/G(1) switch gene 2 (G0S2) protein and mRNA content in human adipose tissue.","date":"2011","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/21613358","citation_count":73,"is_preprint":false},{"pmid":"28645852","id":"PMC_28645852","title":"G0S2: A small giant controller of lipolysis and adipose-liver fatty acid flux.","date":"2017","source":"Biochimica et biophysica acta. Molecular and cell biology of lipids","url":"https://pubmed.ncbi.nlm.nih.gov/28645852","citation_count":72,"is_preprint":false},{"pmid":"26318046","id":"PMC_26318046","title":"Inhibition of adipose triglyceride lipase (ATGL) by the putative tumor suppressor G0S2 or a small molecule inhibitor attenuates the growth of cancer cells.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26318046","citation_count":69,"is_preprint":false},{"pmid":"30770352","id":"PMC_30770352","title":"Targeted Assessment of G0S2 Methylation Identifies a Rapidly Recurrent, Routinely Fatal Molecular Subtype of Adrenocortical Carcinoma.","date":"2019","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/30770352","citation_count":54,"is_preprint":false},{"pmid":"19816938","id":"PMC_19816938","title":"Identification of G0S2 as a gene frequently methylated in squamous lung cancer by combination of in silico and experimental approaches.","date":"2010","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/19816938","citation_count":53,"is_preprint":false},{"pmid":"24302733","id":"PMC_24302733","title":"Defective adipose lipolysis and altered global energy metabolism in mice with adipose overexpression of the lipolytic inhibitor G0/G1 switch gene 2 (G0S2).","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24302733","citation_count":52,"is_preprint":false},{"pmid":"22693613","id":"PMC_22693613","title":"The cytosolic protein G0S2 maintains quiescence in hematopoietic stem cells.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22693613","citation_count":49,"is_preprint":false},{"pmid":"24993166","id":"PMC_24993166","title":"TNF-α reduces g0s2 expression and stimulates lipolysis through PPAR-γ inhibition in 3T3-L1 adipocytes.","date":"2014","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/24993166","citation_count":45,"is_preprint":false},{"pmid":"9428793","id":"PMC_9428793","title":"Cyclosporin A inhibits early mRNA expression of G0/G1 switch gene 2 (G0S2) in cultured human blood mononuclear cells.","date":"1997","source":"DNA and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/9428793","citation_count":43,"is_preprint":false},{"pmid":"25381555","id":"PMC_25381555","title":"Deletion of the gene encoding G0/G 1 switch protein 2 (G0s2) alleviates high-fat-diet-induced weight gain and insulin resistance, and promotes browning of white adipose tissue in mice.","date":"2014","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/25381555","citation_count":41,"is_preprint":false},{"pmid":"26837760","id":"PMC_26837760","title":"G0S2 Suppresses Oncogenic Transformation by Repressing a MYC-Regulated Transcriptional Program.","date":"2016","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/26837760","citation_count":38,"is_preprint":false},{"pmid":"18636162","id":"PMC_18636162","title":"G0S2 is an all-trans-retinoic acid target gene.","date":"2008","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/18636162","citation_count":37,"is_preprint":false},{"pmid":"29209111","id":"PMC_29209111","title":"Palmitate induces fat accumulation by activating C/EBPβ-mediated G0S2 expression in HepG2 cells.","date":"2017","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/29209111","citation_count":37,"is_preprint":false},{"pmid":"19878646","id":"PMC_19878646","title":"Impact of DNA demethylation of the G0S2 gene on the transcription of G0S2 in squamous lung cancer cell lines with or without nuclear receptor agonists.","date":"2009","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/19878646","citation_count":36,"is_preprint":false},{"pmid":"35769488","id":"PMC_35769488","title":"Single-Cell Sequencing Analysis and Multiple Machine Learning Methods Identified G0S2 and HPSE as Novel Biomarkers for Abdominal Aortic Aneurysm.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35769488","citation_count":35,"is_preprint":false},{"pmid":"30085885","id":"PMC_30085885","title":"Disruption of G0/G1 switch gene 2 ( G0S2) reduced abdominal fat deposition and altered fatty acid composition in chicken.","date":"2018","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/30085885","citation_count":33,"is_preprint":false},{"pmid":"24556704","id":"PMC_24556704","title":"Mice lacking G0S2 are lean and cold-tolerant.","date":"2014","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/24556704","citation_count":32,"is_preprint":false},{"pmid":"30953555","id":"PMC_30953555","title":"Lipolytic inhibitor G0S2 modulates glioma stem-like cell radiation response.","date":"2019","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/30953555","citation_count":31,"is_preprint":false},{"pmid":"24183236","id":"PMC_24183236","title":"G0S2 inhibits the proliferation of K562 cells by interacting with nucleolin in the cytosol.","date":"2013","source":"Leukemia research","url":"https://pubmed.ncbi.nlm.nih.gov/24183236","citation_count":31,"is_preprint":false},{"pmid":"9680722","id":"PMC_9680722","title":"An alternative way of thinking about stem-loops in DNA. A case study of the human G0S2 gene.","date":"1998","source":"Journal of theoretical biology","url":"https://pubmed.ncbi.nlm.nih.gov/9680722","citation_count":27,"is_preprint":false},{"pmid":"32334290","id":"PMC_32334290","title":"Cooperative application of transcriptomics and ceRNA hypothesis: LncRNA-107052630/miR-205a/G0S2 crosstalk is involved in ammonia-induced intestinal apoptotic injury in chicken.","date":"2020","source":"Journal of hazardous materials","url":"https://pubmed.ncbi.nlm.nih.gov/32334290","citation_count":27,"is_preprint":false},{"pmid":"23322075","id":"PMC_23322075","title":"Porcine G₀/G₁ switch gene 2 (G0S2) expression is regulated during adipogenesis and short-term in-vivo nutritional interventions.","date":"2013","source":"Lipids","url":"https://pubmed.ncbi.nlm.nih.gov/23322075","citation_count":23,"is_preprint":false},{"pmid":"37442366","id":"PMC_37442366","title":"Acidosis-induced regulation of adipocyte G0S2 promotes crosstalk between adipocytes and breast cancer cells as well as tumor progression.","date":"2023","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/37442366","citation_count":19,"is_preprint":false},{"pmid":"27248498","id":"PMC_27248498","title":"Regulation of G0/G1 Switch Gene 2 (G0S2) Protein Ubiquitination and Stability by Triglyceride Accumulation and ATGL Interaction.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27248498","citation_count":18,"is_preprint":false},{"pmid":"35292727","id":"PMC_35292727","title":"G0S2 regulates innate immunity in Kawasaki disease via lncRNA HSD11B1-AS1.","date":"2022","source":"Pediatric research","url":"https://pubmed.ncbi.nlm.nih.gov/35292727","citation_count":16,"is_preprint":false},{"pmid":"25666096","id":"PMC_25666096","title":"G0S2 modulates homeostatic proliferation of naïve CD8⁺ T cells and inhibits oxidative phosphorylation in mitochondria.","date":"2015","source":"Immunology and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/25666096","citation_count":16,"is_preprint":false},{"pmid":"30802154","id":"PMC_30802154","title":"Identification of an intrinsic lysophosphatidic acid acyltransferase activity in the lipolytic inhibitor G0/G1 switch gene 2 (G0S2).","date":"2019","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/30802154","citation_count":16,"is_preprint":false},{"pmid":"28910567","id":"PMC_28910567","title":"G0S2 represses PI3K/mTOR signaling and increases sensitivity to PI3K/mTOR pathway inhibitors in breast cancer.","date":"2017","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/28910567","citation_count":15,"is_preprint":false},{"pmid":"36536477","id":"PMC_36536477","title":"Loss of G0/G1 switch gene 2 (G0S2) promotes disease progression and drug resistance in chronic myeloid leukaemia (CML) by disrupting glycerophospholipid metabolism.","date":"2022","source":"Clinical and translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36536477","citation_count":15,"is_preprint":false},{"pmid":"29556076","id":"PMC_29556076","title":"The Nuclear Orphan Receptor Nur77 Alleviates Palmitate-induced Fat Accumulation by Down-regulating G0S2 in HepG2 Cells.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29556076","citation_count":14,"is_preprint":false},{"pmid":"27117803","id":"PMC_27117803","title":"Pronounced expression of the lipolytic inhibitor G0/G1 Switch Gene 2 (G0S2) in adipose tissue from brown bears (Ursus arctos) prior to hibernation.","date":"2016","source":"Physiological reports","url":"https://pubmed.ncbi.nlm.nih.gov/27117803","citation_count":14,"is_preprint":false},{"pmid":"25448749","id":"PMC_25448749","title":"Progesterone-induced down-regulation of hormone sensitive lipase (Lipe) and up-regulation of G0/G1 switch 2 (G0s2) genes expression in inguinal adipose tissue of female rats is reflected by diminished rate of lipolysis.","date":"2014","source":"The Journal of steroid biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/25448749","citation_count":14,"is_preprint":false},{"pmid":"26511521","id":"PMC_26511521","title":"Increases in skeletal muscle ATGL and its inhibitor G0S2 following 8 weeks of endurance training in metabolically different rat skeletal muscles.","date":"2015","source":"American journal of physiology. Regulatory, integrative and comparative physiology","url":"https://pubmed.ncbi.nlm.nih.gov/26511521","citation_count":13,"is_preprint":false},{"pmid":"31916304","id":"PMC_31916304","title":"In vivo real-time ATP imaging in zebrafish hearts reveals G0s2 induces ischemic tolerance.","date":"2020","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/31916304","citation_count":11,"is_preprint":false},{"pmid":"35026402","id":"PMC_35026402","title":"Residues of the minimal sequence of G0S2 collectively contribute to ATGL inhibition while C-and N-terminal extensions promote binding to ATGL.","date":"2022","source":"Biochimica et biophysica acta. Molecular and cell biology of lipids","url":"https://pubmed.ncbi.nlm.nih.gov/35026402","citation_count":11,"is_preprint":false},{"pmid":"37244968","id":"PMC_37244968","title":"JAZF1 safeguards human endometrial stromal cells survival and decidualization by repressing the transcription of G0S2.","date":"2023","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/37244968","citation_count":10,"is_preprint":false},{"pmid":"34815115","id":"PMC_34815115","title":"Promotion effect of salt on intramuscular neutral lipid hydrolysis during dry-salting process of porcine (biceps femoris) muscles by inducing phosphorylation of ATGL, HSL and their regulatory proteins of Perilipin1, ABHD5 and G0S2.","date":"2021","source":"Food chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34815115","citation_count":9,"is_preprint":false},{"pmid":"27624922","id":"PMC_27624922","title":"Liver-specific G0 /G1 switch gene 2 (G0s2) expression promotes hepatic insulin resistance by exacerbating hepatic steatosis in male Wistar rats.","date":"2016","source":"Journal of diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/27624922","citation_count":9,"is_preprint":false},{"pmid":"37086619","id":"PMC_37086619","title":"G0S2 promotes antiestrogenic and pro-migratory responses in ER+ and ER- breast cancer cells.","date":"2023","source":"Translational oncology","url":"https://pubmed.ncbi.nlm.nih.gov/37086619","citation_count":8,"is_preprint":false},{"pmid":"35405904","id":"PMC_35405904","title":"G0S2 Gene Polymorphism and Its Relationship with Carcass Traits in Chicken.","date":"2022","source":"Animals : an open access journal from MDPI","url":"https://pubmed.ncbi.nlm.nih.gov/35405904","citation_count":7,"is_preprint":false},{"pmid":"40288593","id":"PMC_40288593","title":"FXR as a pivotal role linking JNK and G0s2 mitigates triptolide-induced hepatotoxicity through the regulation of metabolic disorder of liver.","date":"2025","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/40288593","citation_count":7,"is_preprint":false},{"pmid":"26707160","id":"PMC_26707160","title":"Regulation of G0/G1 switch gene 2 (G0S2) expression in human adipose tissue.","date":"2016","source":"Archives of physiology and biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26707160","citation_count":6,"is_preprint":false},{"pmid":"33061827","id":"PMC_33061827","title":"The Expression Pattern and Regulatory Mechanism of the G0/G1 Switch Gene 2 (G0S2) in the Pathogenesis and Treatment of AChR Myasthenia Gravis (MG).","date":"2020","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/33061827","citation_count":6,"is_preprint":false},{"pmid":"24487091","id":"PMC_24487091","title":"Tissue expression pattern and polymorphism of G0S2 gene in porcine.","date":"2014","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/24487091","citation_count":5,"is_preprint":false},{"pmid":"36660674","id":"PMC_36660674","title":"G0S2 ameliorates oxidized low-density lipoprotein-induced vascular endothelial cell injury by regulating mitochondrial apoptosis.","date":"2022","source":"Annals of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36660674","citation_count":5,"is_preprint":false},{"pmid":"25811590","id":"PMC_25811590","title":"Characterization of lipolytic inhibitor G(0)/G(1) switch gene-2 protein (G0S2) expression in male Sprague-Dawley rat skeletal muscle compared to relative content of adipose triglyceride lipase (ATGL) and comparitive gene identification-58 (CGI-58).","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25811590","citation_count":5,"is_preprint":false},{"pmid":"40100923","id":"PMC_40100923","title":"Absence of the intracellular lipolytic inhibitor G0S2 enhances intravascular triglyceride clearance and abolishes diet-induced hypertriglyceridemia.","date":"2025","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/40100923","citation_count":4,"is_preprint":false},{"pmid":"36420951","id":"PMC_36420951","title":"Identification of motifs and mechanisms for lipid droplet targeting of the lipolytic inhibitors G0S2 and HIG2.","date":"2022","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/36420951","citation_count":4,"is_preprint":false},{"pmid":"27605212","id":"PMC_27605212","title":"Activation of G0S2 is coordinated by recruitment of PML/RARα and C/EBPε to its promoter during ATRA-induced APL differentiation.","date":"2016","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/27605212","citation_count":4,"is_preprint":false},{"pmid":"40679675","id":"PMC_40679675","title":"Recent advances on the role of G0S2.","date":"2025","source":"Discover oncology","url":"https://pubmed.ncbi.nlm.nih.gov/40679675","citation_count":3,"is_preprint":false},{"pmid":"37033250","id":"PMC_37033250","title":"The effect of G0S2 on insulin sensitivity: A proteomic analysis in a G0S2-overexpressed high-fat diet mouse model.","date":"2023","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/37033250","citation_count":3,"is_preprint":false},{"pmid":"39707168","id":"PMC_39707168","title":"Mutation on JmjC domain of UTX impaired its antitumor effects in pancreatic cancer via inhibiting G0S2 expression and activating the Toll-like signaling pathway.","date":"2024","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/39707168","citation_count":2,"is_preprint":false},{"pmid":"40242964","id":"PMC_40242964","title":"BCL2A1‑ and G0S2‑driven neutrophil extracellular traps: A protective mechanism linking preeclampsia to reduced breast cancer risk.","date":"2025","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/40242964","citation_count":2,"is_preprint":false},{"pmid":"34260600","id":"PMC_34260600","title":"Biophysical characterization and a roadmap towards the NMR solution structure of G0S2, a key enzyme in non-alcoholic fatty liver disease.","date":"2021","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/34260600","citation_count":2,"is_preprint":false},{"pmid":"31358019","id":"PMC_31358019","title":"Correction to: Lipolytic inhibitor G0S2 modulates glioma stem-like cell radiation response.","date":"2019","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/31358019","citation_count":2,"is_preprint":false},{"pmid":"26654706","id":"PMC_26654706","title":"Deletion of the putative tumor suppressor gene, G0s2, does not affect progression of Eμ-Myc driven lymphomas in mice.","date":"2015","source":"Leukemia research","url":"https://pubmed.ncbi.nlm.nih.gov/26654706","citation_count":2,"is_preprint":false},{"pmid":"40568952","id":"PMC_40568952","title":"PIK3R1 and G0S2 are human placenta-specific imprinted genes associated with germline-inherited maternal DNA methylation.","date":"2025","source":"Epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/40568952","citation_count":1,"is_preprint":false},{"pmid":"36366842","id":"PMC_36366842","title":"Gastric Cancer Growth Modulated by circSNTB2/miR-6938-5p/G0S2 and PDCD4.","date":"2023","source":"Combinatorial chemistry & high throughput screening","url":"https://pubmed.ncbi.nlm.nih.gov/36366842","citation_count":1,"is_preprint":false},{"pmid":"40282408","id":"PMC_40282408","title":"G0S2 Promotes PD-L1 Expression in Monocytes and Influences the Efficacy of PD-1 Inhibitors in Hepatocellular Carcinoma.","date":"2025","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/40282408","citation_count":1,"is_preprint":false},{"pmid":"40218345","id":"PMC_40218345","title":"The Effect of G0S2 Gene Knockout on the Proliferation, Apoptosis, and Differentiation of Chicken Preadipocytes.","date":"2025","source":"Animals : an open access journal from MDPI","url":"https://pubmed.ncbi.nlm.nih.gov/40218345","citation_count":1,"is_preprint":false},{"pmid":"41223328","id":"PMC_41223328","title":"An Extracellular Matrix-Producing Subset of Cancer-Associated Fibroblasts Drives Chemoresistance in Breast Cancer via SRC Activation and G0S2 Upregulation.","date":"2026","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/41223328","citation_count":1,"is_preprint":false},{"pmid":"39989302","id":"PMC_39989302","title":"The Evaluation of PNPLA2, ATGL, and G0S2 Levels in Serum and PBMCs of the Newly Diagnosed and the Chronic Patients With Rheumatoid Arthritis.","date":"2025","source":"International journal of rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/39989302","citation_count":1,"is_preprint":false},{"pmid":"40519301","id":"PMC_40519301","title":"Metabolic profiling of glioblastoma and identification of G0S2 as a metabolic target.","date":"2025","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/40519301","citation_count":0,"is_preprint":false},{"pmid":"39667714","id":"PMC_39667714","title":"The repression of the lipolytic inhibitor G0s2 enhancers affects lipid metabolism.","date":"2024","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/39667714","citation_count":0,"is_preprint":false},{"pmid":"40185884","id":"PMC_40185884","title":"G0S2 modulates normal vitreous-induced proliferation in endothelial cells.","date":"2025","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/40185884","citation_count":0,"is_preprint":false},{"pmid":"42193761","id":"PMC_42193761","title":"Novel Insights into G0S2 as a Central Regulator of Lipid Metabolism and Its Implications for Meat Quality.","date":"2026","source":"Animals : an open access journal from MDPI","url":"https://pubmed.ncbi.nlm.nih.gov/42193761","citation_count":0,"is_preprint":false},{"pmid":"41985712","id":"PMC_41985712","title":"G0S2 drives lipid metabolism disorders and oxidative stress to promote M1 macrophage polarization and inflammation in polycystic ovary syndrome.","date":"2026","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/41985712","citation_count":0,"is_preprint":false},{"pmid":"31311601","id":"PMC_31311601","title":"Correction to: Lipolytic inhibitor G0S2 modulates glioma stem-like cell radiation response.","date":"2019","source":"Journal of orthopaedic surgery and research","url":"https://pubmed.ncbi.nlm.nih.gov/31311601","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.03.19.644086","title":"Genome-wide transcriptomic response of whole blood to radiation","date":"2025-03-19","source":"bioRxiv","url":"https://doi.org/10.1101/2025.03.19.644086","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.07.30.605812","title":"Central activation of catecholamine-independent lipolysis drives the end-stage catabolism of all adipose tissues","date":"2024-07-31","source":"bioRxiv","url":"https://doi.org/10.1101/2024.07.30.605812","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":39433,"output_tokens":6251,"usd":0.106032,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":15206,"output_tokens":5644,"usd":0.108565,"stage2_stop_reason":"end_turn"},"total_usd":0.214597,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2009,\n      \"finding\": \"G0S2 encodes a mitochondria-localized protein that directly binds Bcl-2 and promotes apoptosis by preventing the formation of protective Bcl-2/Bax heterodimers; G0S2 lacks Bcl-2 homology domains but antagonizes Bcl-2 antiapoptotic activity. Expression is induced by TNF-alpha through NF-κB.\",\n      \"method\": \"Co-immunoprecipitation, subcellular fractionation, ectopic expression in cancer cell lines, expression profiling with NF-κB inhibition\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP demonstrating Bcl-2 binding, subcellular fractionation for localization, functional apoptosis assays; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"19706769\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"G0S2 acts as a direct inhibitor of adipose triglyceride lipase (ATGL) activity and ATGL-mediated lipolysis. G0S2 binds ATGL independently of ATGL's activity state or the presence of CGI-58. Combined expression of CGI-58 and ATGL cannot stimulate lipid droplet turnover in G0S2-expressing cells, indicating G0S2 and CGI-58 regulate ATGL via non-competing mechanisms.\",\n      \"method\": \"Co-immunoprecipitation, lipid droplet morphology assays, lipolysis assays in cells overexpressing G0S2, CGI-58 and ATGL constructs\",\n      \"journal\": \"Cell cycle (Georgetown, Tex.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct binding demonstrated by Co-IP, functional lipolysis assays, replicated across multiple subsequent studies from independent labs\",\n      \"pmids\": [\"20676045\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"The minimal active domain of ATGL required for inhibition by G0S2 ranges from amino acids Ile10 to Leu254. This minimal fragment retains both protein-protein interaction with G0S2 and susceptibility to G0S2-mediated inhibition, implying G0S2 interacts with the patatin-domain region of ATGL.\",\n      \"method\": \"Truncation mutagenesis, in vitro lipase activity assays, protein-protein interaction assays, 3D homology modeling\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro lipase activity assays with defined truncation mutants plus structural homology modeling; single lab but multiple orthogonal biochemical methods\",\n      \"pmids\": [\"22039468\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"G0S2 is a direct transcriptional target of retinoic acid (RA) signaling. Retinoic acid response element (RARE) half-sites in the G0S2 promoter are required for RA-mediated transcriptional activation; mutation of these sites blocks activation. RAR co-transfection assays confirmed transcriptional activation after RA treatment. G0S2 protein is rapidly induced in APL cells and APL transgenic mice treated with RA in an RAR-dependent manner.\",\n      \"method\": \"Reporter gene assays with RARE site mutagenesis, RAR co-transfection, actinomycin D/cycloheximide treatment, RT-PCR, polyclonal antibody detection of protein\",\n      \"journal\": \"International journal of oncology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — promoter reporter assays with site-directed mutagenesis of RARE sites, confirmed at protein level; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"18636162\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"G0S2 localizes to mitochondria, endoplasmic reticulum, and early endosomes in hematopoietic cells. The hydrophobic domain of G0S2 interacts with the RGG-repeat domain of nucleolin, retaining nucleolin in the cytosol; this cytosolic retention of nucleolin occurs in resting but not proliferating hematopoietic stem cells. G0S2 overexpression increases HSC quiescence while G0S2 knockdown promotes HSC division.\",\n      \"method\": \"Retroviral overexpression, shRNA knockdown, bone marrow transplantation, cell cycle analysis, proteomic identification of binding partners (nucleolin), subcellular fractionation/imaging\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain- and loss-of-function in primary HSCs with defined phenotype (quiescence), proteomic identification of nucleolin interaction, localization data; single lab\",\n      \"pmids\": [\"22693613\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"G0S2 inhibits proliferation of K562 leukemia cells by sequestering nucleolin in the cytosol, preventing its pro-proliferative functions in the nucleolus. Knockdown of G0S2 by shRNA in 5-azacytidine-treated K562 cells restores proliferation.\",\n      \"method\": \"5-azacytidine demethylation, shRNA knockdown, xenograft models, co-immunoprecipitation/interaction assays with nucleolin, proliferation assays\",\n      \"journal\": \"Leukemia research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function rescue experiment, binding to nucleolin demonstrated, in vivo xenograft; single lab\",\n      \"pmids\": [\"24183236\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Adipose-specific overexpression of G0S2 in transgenic mice inhibits basal and adrenergically stimulated lipolysis in adipose explants, reduces in vivo lipolysis and ketogenesis during fasting, impairs the metabolic shift from carbohydrates to fatty acids, and promotes lipid droplet accumulation in brown adipocytes with defective cold adaptation.\",\n      \"method\": \"Adipose-specific transgenic mouse model, lipolysis assays in adipose explants, in vivo metabolic measurements, β3-adrenergic agonist injection, cold tolerance tests, high-fat diet feeding\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo genetic model with multiple metabolic phenotype readouts including direct lipolysis assays; rigorous transgenic mouse study\",\n      \"pmids\": [\"24302733\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Deletion of G0s2 in mice leads to a lean phenotype with enhanced adipose lipase activity, increased stimulated lipolysis in adipocytes, resistance to high-fat diet weight gain, improved glucose and insulin tolerance, and enhanced 'browning' of white adipose tissue with upregulation of thermoregulatory genes.\",\n      \"method\": \"G0s2 knockout mouse generation, lipolysis assays, metabolic phenotyping (body composition, glucose/insulin tolerance tests, energy metabolism), gene expression analysis\",\n      \"journal\": \"Diabetologia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — complete knockout mouse with multiple orthogonal metabolic phenotype readouts; replicated by another lab (PMID 24556704)\",\n      \"pmids\": [\"25381555\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"G0s2-null mice are lean with increased serum glycerol (indicating enhanced lipolysis), decreased gonadal fat pad weight, improved cold tolerance, and augmented thermogenic gene expression. G0S2 is most highly expressed in adipose tissue.\",\n      \"method\": \"G0s2 knockout mouse, body composition analysis, serum glycerol measurement, cold tolerance tests, tissue expression profiling\",\n      \"journal\": \"Cancer biology & therapy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — independent knockout mouse study replicating lean phenotype and lipolysis findings; corroborates PMID 25381555\",\n      \"pmids\": [\"24556704\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"G0S2 protein is degraded via K48-linked polyubiquitination at lysine-25. Mutation of K25 abolishes ubiquitination and increases protein stability. G0S2 protein is stabilized by ATGL expression and by fatty acid-induced triglyceride accumulation through distinct mechanisms. G0S2 protein levels are reduced in adipose tissue of ATGL-deficient mice.\",\n      \"method\": \"Site-directed mutagenesis of K25, ubiquitination assays, proteasome inhibitor treatment, co-expression with ATGL, fatty acid treatment, ATGL-knockout mouse adipose tissue analysis\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct mutagenesis of ubiquitination site combined with biochemical ubiquitination assays and in vivo validation in ATGL-KO mice; multiple orthogonal methods\",\n      \"pmids\": [\"27248498\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"G0S2 suppresses oncogene-induced transformation independently of ATGL inhibition. G0s2-null MEFs are readily transformed by HRAS or EGFR; restoration of G0S2 reverses HRAS-driven transformation. Gene expression analysis reveals upregulation of MYC target signatures in G0s2-null MEFs; RNAi or pharmacologic inhibition of MYC abrogates transformation.\",\n      \"method\": \"G0s2-null MEFs, oncogene transformation assays (HRAS, EGFR), G0S2 rescue expression, gene expression profiling, MYC RNAi and pharmacologic inhibition\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic null MEFs with rescue, epistasis via MYC inhibition; single lab with multiple methods\",\n      \"pmids\": [\"26837760\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"During ATRA-induced APL differentiation, PML/RARα is recruited to the G0S2 promoter in an ATRA-dependent (ligand-dependent) manner and cooperates physically and functionally with C/EBPε (specifically the p30 isoform) to activate G0S2 transcription. ChIP-qPCR demonstrated co-occupancy of PML/RARα and C/EBPε at the G0S2 promoter.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP)-qPCR in NB4 and PR9 cell lines and primary APL cells, co-immunoprecipitation of PML/RARα and C/EBPε, ATRA treatment\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-qPCR in multiple cell types including primary cells, physical interaction demonstrated by Co-IP; single lab\",\n      \"pmids\": [\"27605212\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"G0S2 possesses an intrinsic lysophosphatidic acid acyltransferase (LPAAT) enzymatic activity, directly catalyzing phosphatidic acid synthesis from lysophosphatidic acid and acyl-CoA. A distinct 4-amino acid motif is required for this LPAAT activity. Knockdown of G0S2 in ATGL-deficient mice still decreases hepatic TG content, and overexpression of G0S2 promotes fatty acid incorporation into TGs even in ATGL-deficient hepatocytes, demonstrating a lipolysis-independent TG synthesis function.\",\n      \"method\": \"In vitro LPAAT activity assay, deletion mutagenesis of 4-aa motif, overexpression/knockdown in ATGL-deficient mice and hepatocytes, isotopic fatty acid incorporation assays\",\n      \"journal\": \"FASEB journal : official publication of the Federation of American Societies for Experimental Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro enzymatic assay for LPAAT activity plus mutagenesis of active motif, validated in vivo in ATGL-null mice; multiple orthogonal methods in single study\",\n      \"pmids\": [\"30802154\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"G0S2 inhibits ATGL via non-competitive inhibition by interacting with ATGL's patatin domain. G0S2 inhibition of ATGL reduces lipid droplet turnover and, in glioma stem-like cells, attenuates RNF168-mediated 53BP1 ubiquitination through mTOR-S6K signaling activation and increased 53BP1 protein stability, thereby enhancing DNA repair and radioresistance.\",\n      \"method\": \"G0S2 knockdown/overexpression in GSCs, lipid droplet immunofluorescence, γ-H2AX foci assay, mTOR/S6K pathway analysis, 53BP1 ubiquitination assay, xenograft survival experiments\",\n      \"journal\": \"Journal of experimental & clinical cancer research : CR\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic gain/loss-of-function with mechanistic pathway readouts (mTOR-S6K-53BP1) and in vivo xenograft; single lab\",\n      \"pmids\": [\"30953555\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"In zebrafish, G0s2 functions as a positive regulator of oxidative phosphorylation (OXPHOS) and maintains intra-mitochondrial ATP concentration under hypoxia. TALEN-mediated g0s2 knockout abolishes hypoxic tolerance in zebrafish hearts, while cardiomyocyte-specific overexpression confers strong ischemic tolerance. In vivo FRET-based ATP biosensor imaging showed that g0s2-expressing cardiomyocytes maintain ATP production and contractility during hypoxia.\",\n      \"method\": \"TALEN knockout zebrafish, cardiomyocyte-specific transgenic zebrafish, in vivo mitochondria-targeted FRET ATP biosensor imaging, mosaic overexpression model\",\n      \"journal\": \"FASEB journal : official publication of the Federation of American Societies for Experimental Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vivo real-time ATP imaging with FRET biosensor, genetic loss- and gain-of-function, side-by-side cell comparison; multiple orthogonal methods\",\n      \"pmids\": [\"31916304\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"G0S2 inhibits energy production by oxidative phosphorylation in naïve CD8+ T cells. G0S2-null naïve CD8+ T cells display increased basal and spare respiratory capacity associated with increased AMPK-α phosphorylation, not increased mitochondrial biogenesis. G0S2 expression in naïve T cells is suppressed downstream of TCR activation via MAPK, calcium/calmodulin, PI3K, and mTOR pathways.\",\n      \"method\": \"G0s2-null mice, Seahorse respirometry, mitochondrial biogenesis markers, AMPK phosphorylation analysis, T cell activation assays, in vivo lymphopenia-induced proliferation\",\n      \"journal\": \"Immunology and cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout with Seahorse respirometry (direct mitochondrial function readout) and AMPK signaling analysis; single lab\",\n      \"pmids\": [\"25666096\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The minimal sequence of G0S2 required for ATGL inhibition spans amino acids 20–44, containing a hydrophobic region. Residues Y27, V28, G30, A34, G37, V39, and L42 play substantial roles in ATGL inhibition. N-terminal extensions (aa 20–27) facilitate non-specific interactions that increase binding to ATGL. Full-length G0S2 shows greater tolerance to single amino acid exchanges due to stronger contributions of these flanking interactions.\",\n      \"method\": \"Site-directed mutagenesis, truncation analysis, in vitro ATGL lipase activity assays, binding assays with G0S2 variants\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular and cell biology of lipids\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — systematic site-directed mutagenesis and truncation validated by in vitro lipase activity assays; single lab but comprehensive per-residue mutagenesis\",\n      \"pmids\": [\"35026402\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ATGL-independent localization of G0S2 to both the endoplasmic reticulum (ER) and lipid droplets (LDs) is mediated by a hairpin structure consisting of two hydrophobic sequences. Positively charged residues in the hinge region of this hairpin sort G0S2 from ER to LDs. When ATGL is co-expressed, the role of these positive charges in LD sorting becomes dispensable.\",\n      \"method\": \"Structural prediction, cell imaging with fluorescent-tagged constructs, mutagenesis of hydrophobic sequences and charged residues, co-expression with ATGL\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell imaging with mutant constructs identifying structural determinants; single lab, multiple mutants tested\",\n      \"pmids\": [\"36420951\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"TNF-α reduces G0S2 expression in adipocytes through proteasomal degradation of PPARγ, which abolishes PPARγ binding to the G0S2 promoter. Proteasome inhibition (MG-132) maintains PPARγ levels and preserves G0S2 expression. Overexpression of G0S2 or PPARγ partially reverses TNF-α-induced lipolysis.\",\n      \"method\": \"3T3-L1 adipocyte differentiation, TNF-α treatment, proteasome inhibitor MG-132, ChIP assay for PPARγ binding to G0S2 promoter, G0S2 and PPARγ overexpression, lipolysis assays\",\n      \"journal\": \"Cytokine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP demonstrating PPARγ promoter binding, proteasome inhibitor rescue, functional lipolysis assay; single lab\",\n      \"pmids\": [\"24993166\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"JAZF1 represses G0S2 transcription in human endometrial stromal cells (hESCs) by interacting with the G0S2 transcriptional activator Purβ, restricting its activity. JAZF1 depletion leads to increased G0S2 expression, apoptosis, and defective decidualization. G0S2 was identified as a key driver of hESC apoptosis in this context.\",\n      \"method\": \"JAZF1 siRNA/overexpression in hESCs, G0S2 promoter analysis, co-immunoprecipitation of JAZF1 with Purβ, decidualization assays, apoptosis assays, patient tissue analysis\",\n      \"journal\": \"Communications biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP of JAZF1-Purβ interaction with G0S2 promoter reporter assays and loss-of-function phenotype; single lab\",\n      \"pmids\": [\"37244968\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Genetic ablation of G0S2 in mice completely abolishes diet-induced hypertriglyceridemia and attenuates atherogenesis by enhancing whole-body triglyceride clearance. G0S2 deletion increases circulating LPL concentration and activity predominantly from white adipose tissue (WAT), and enhances LPL protein stability in adipocytes. This effect is reversed by ATGL inhibition, linking intracellular ATGL activity (regulated by G0S2) to extracellular LPL-mediated lipolysis. WAT transplantation from G0S2-deficient mice normalizes plasma TG levels in hypertriglyceridemic mice.\",\n      \"method\": \"G0S2 global knockout mice, WAT transplantation, LPL activity and concentration measurement, ATGL inhibitor treatment, dietary lipid challenge, atherosclerosis assessment\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo genetic ablation with WAT transplantation rescue, LPL activity measurements, ATGL inhibitor epistasis; multiple orthogonal approaches in single rigorous study\",\n      \"pmids\": [\"40100923\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"In a mouse model of brain-evoked catabolism of all adipose depots, downregulation of G0s2 (along with Acvr1c and Npr3) is part of the cell-autonomous lipolytic inhibitor suppression that activates catecholamine-independent lipolysis, enabling mobilization of stable adipose stores including bone marrow adipose tissue. This process requires ATGL-dependent lipolysis.\",\n      \"method\": \"Genetic, surgical, and chemical intervention mouse models; adipose-specific gene expression analysis; G0s2 expression profiling during cachexia/starvation models\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — G0s2 identified as one of several inhibitors downregulated in a complex model; specific mechanistic role of G0s2 not isolated; preprint\",\n      \"pmids\": [\"bio_10.1101_2024.07.30.605812\"],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"G0S2 is a small, mitochondria/ER/lipid-droplet-localized protein that functions as a potent endogenous non-competitive inhibitor of adipose triglyceride lipase (ATGL) by binding ATGL's patatin domain through a conserved hydrophobic region (residues 20–44), thereby suppressing intracellular lipolysis; it also possesses an intrinsic lysophosphatidic acid acyltransferase (LPAAT) activity promoting triglyceride synthesis; beyond lipid metabolism it antagonizes Bcl-2 antiapoptotic function by disrupting Bcl-2/Bax heterodimers, promotes cellular quiescence by sequestering nucleolin in the cytosol, positively regulates mitochondrial ATP production/oxidative phosphorylation, and is transcriptionally regulated by NF-κB (TNF-α), RARα/RARE elements (retinoic acid), PPARγ (via C/EBPβ), and the PML/RARα–C/EBPε complex in APL cells, while its own protein stability is controlled by K48-linked polyubiquitination at K25 and is stabilized by ATGL interaction and triglyceride accumulation.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"G0S2 is a small, multi-localized regulatory protein whose dominant characterized role is the suppression of intracellular triglyceride lipolysis through direct, non-competitive inhibition of adipose triglyceride lipase (ATGL) [#1, #13]. G0S2 binds the patatin-domain region of ATGL independently of ATGL's activity state or the co-activator CGI-58, and this inhibition operates by a mechanism distinct from CGI-58-mediated activation [#1, #2]. The minimal inhibitory determinant is a hydrophobic region spanning residues 20\\u201344, with specific residues (Y27, V28, G30, A34, G37, V39, L42) driving ATGL inhibition [#16]; a hairpin of two hydrophobic sequences with charged hinge residues directs ATGL-independent sorting of G0S2 between the endoplasmic reticulum and lipid droplets [#17]. In vivo, adipose-specific overexpression suppresses basal and stimulated lipolysis, ketogenesis, and the carbohydrate-to-fat metabolic shift [#6], whereas G0s2 deletion produces a lean, lipolysis-enhanced phenotype with improved glucose tolerance and adipose browning [#7, #8], and abolishes diet-induced hypertriglyceridemia and atherogenesis by coupling intracellular ATGL activity to extracellular LPL-mediated triglyceride clearance [#20]. Independent of lipolysis inhibition, G0S2 carries an intrinsic lysophosphatidic acid acyltransferase activity that promotes triglyceride synthesis [#12]. Beyond lipid metabolism, G0S2 antagonizes Bcl-2 antiapoptotic function by disrupting Bcl-2/Bax heterodimers [#0], enforces hematopoietic and leukemic cell quiescence by sequestering nucleolin in the cytosol via its hydrophobic domain [#4, #5], suppresses oncogene-induced transformation through a MYC-dependent mechanism [#10], and regulates mitochondrial oxidative phosphorylation and ATP output [#14, #15]. G0S2 transcription is controlled by retinoic acid through RARE elements [#3], by the PML/RAR\\u03b1\\u2013C/EBP\\u03b5 complex in APL cells [#11], and by PPAR\\u03b3, whose TNF-\\u03b1-driven degradation lowers G0S2 [#18], while G0S2 protein stability is set by K48-linked polyubiquitination at K25 and is stabilized by ATGL binding and triglyceride accumulation [#9].\",\n  \"teleology\": [\n    {\n      \"year\": 2008,\n      \"claim\": \"Establishing how G0S2 is induced linked it to retinoic acid signaling, identifying the first defined transcriptional input.\",\n      \"evidence\": \"RARE-site reporter mutagenesis and RAR co-transfection in APL cells and transgenic mice\",\n      \"pmids\": [\"18636162\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address G0S2 protein function downstream of induction\", \"Other transcriptional inputs unexplored at this stage\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"The first functional assignment placed G0S2 at mitochondria as a pro-apoptotic antagonist of Bcl-2, establishing a non-metabolic role.\",\n      \"evidence\": \"Reciprocal Co-IP, subcellular fractionation, and apoptosis assays in cancer cell lines with NF-\\u03baB-inhibition expression profiling\",\n      \"pmids\": [\"19706769\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis of Bcl-2 binding without BH domains unresolved\", \"Relationship to later lipid functions not addressed\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Identification of G0S2 as a direct ATGL inhibitor defined its central metabolic function and distinguished it mechanistically from CGI-58.\",\n      \"evidence\": \"Co-IP and lipolysis/lipid droplet assays in cells co-expressing G0S2, CGI-58, and ATGL\",\n      \"pmids\": [\"20676045\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Inhibition mechanism (competitive vs non-competitive) not yet defined\", \"Binding interface on ATGL not mapped\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Mapping the ATGL fragment required for inhibition localized the G0S2 interaction to the patatin domain, advancing structural understanding of the inhibitory complex.\",\n      \"evidence\": \"Truncation mutagenesis, in vitro lipase assays, and 3D homology modeling\",\n      \"pmids\": [\"22039468\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"G0S2 residues mediating contact not yet defined\", \"No co-crystal structure\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Discovery of nucleolin sequestration explained a lipolysis-independent role in enforcing hematopoietic stem cell quiescence.\",\n      \"evidence\": \"Retroviral overexpression/shRNA in primary HSCs, proteomic partner identification, fractionation/imaging\",\n      \"pmids\": [\"22693613\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How nucleolin retention links to cell-cycle machinery unclear\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Extending the quiescence mechanism to leukemia showed G0S2 restrains proliferation by cytosolic nucleolin sequestration in K562 cells.\",\n      \"evidence\": \"5-azacytidine demethylation, shRNA rescue, nucleolin interaction assays, and xenografts\",\n      \"pmids\": [\"24183236\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Generality across leukemia subtypes untested\", \"Quantitative contribution vs lipid roles unknown\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"An adipose-overexpression mouse confirmed in vivo that G0S2 suppresses lipolysis, ketogenesis, and fuel switching, validating its physiological lipase-inhibitory role.\",\n      \"evidence\": \"Adipose-specific transgenic mice with lipolysis assays, fasting metabolism, and cold-tolerance tests\",\n      \"pmids\": [\"24302733\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous regulation under physiological states not addressed by overexpression\", \"Tissue-specific contributions beyond adipose unexamined\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Loss-of-function mouse studies established the reciprocal phenotype, showing G0s2 deletion drives leanness, enhanced lipolysis, browning, and improved glucose handling.\",\n      \"evidence\": \"Two independent G0s2 knockout mouse lines with metabolic phenotyping and tissue expression profiling\",\n      \"pmids\": [\"25381555\", \"24556704\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of WAT browning downstream of G0S2 loss not dissected\", \"Effects on non-adipose tissues underexplored\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Linking TNF-\\u03b1 to PPAR\\u03b3 degradation explained how inflammatory signaling lowers G0S2 transcription and de-represses lipolysis.\",\n      \"evidence\": \"3T3-L1 adipocytes, ChIP for PPAR\\u03b3 promoter binding, MG-132 rescue, and lipolysis assays\",\n      \"pmids\": [\"24993166\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct PPAR\\u03b3 response element not finely mapped\", \"Interplay with other transcriptional inputs unaddressed\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Demonstrating that G0S2 restrains oxidative phosphorylation in naive CD8+ T cells extended its role to mitochondrial bioenergetics and immune cell metabolism.\",\n      \"evidence\": \"G0s2-null mice, Seahorse respirometry, AMPK phosphorylation, and TCR-pathway analysis\",\n      \"pmids\": [\"25666096\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular target within OXPHOS machinery unidentified\", \"Apparent opposite direction vs cardiac OXPHOS role unresolved\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Defining K48-polyubiquitination at K25 and ATGL/triglyceride-dependent stabilization revealed how G0S2 protein abundance is post-translationally tuned.\",\n      \"evidence\": \"K25 mutagenesis, ubiquitination and proteasome assays, ATGL co-expression, and ATGL-KO adipose analysis\",\n      \"pmids\": [\"27248498\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Responsible E3 ligase not identified\", \"Mechanism of triglyceride-induced stabilization unresolved\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Showing tumor-suppressive activity independent of ATGL via MYC established a lipolysis-uncoupled function in oncogenic transformation.\",\n      \"evidence\": \"G0s2-null MEFs with HRAS/EGFR transformation assays, rescue, expression profiling, and MYC inhibition\",\n      \"pmids\": [\"26837760\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct molecular link between G0S2 and MYC signaling unknown\", \"Relevance to human tumors not established here\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identifying ligand-dependent PML/RAR\\u03b1 recruitment with C/EBP\\u03b5 to the G0S2 promoter explained how ATRA induces G0S2 during APL differentiation.\",\n      \"evidence\": \"ChIP-qPCR and Co-IP in NB4/PR9 and primary APL cells with ATRA treatment\",\n      \"pmids\": [\"27605212\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of induced G0S2 in differentiation not isolated\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Discovery of intrinsic LPAAT activity revealed that G0S2 actively promotes triglyceride synthesis, a function entirely separate from lipolysis inhibition.\",\n      \"evidence\": \"In vitro LPAAT assays, 4-aa motif mutagenesis, and isotopic FA-incorporation in ATGL-deficient hepatocytes/mice\",\n      \"pmids\": [\"30802154\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of LPAAT vs ATGL-inhibitory function in vivo unclear\", \"Structural basis of catalysis undefined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Defining non-competitive patatin-domain inhibition and connecting G0S2-driven lipid droplet accumulation to mTOR-S6K-53BP1 signaling linked it to DNA repair and radioresistance in glioma stem cells.\",\n      \"evidence\": \"Knockdown/overexpression in GSCs, lipid droplet imaging, \\u03b3-H2AX foci, 53BP1 ubiquitination assays, and xenografts\",\n      \"pmids\": [\"30953555\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanistic chain from lipid droplets to mTOR not fully resolved\", \"Generality beyond glioma untested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Zebrafish genetics established G0S2 as a positive regulator of OXPHOS and mitochondrial ATP under hypoxia, conferring ischemic tolerance.\",\n      \"evidence\": \"TALEN knockout and cardiomyocyte-specific transgenic zebrafish with in vivo FRET ATP biosensor imaging\",\n      \"pmids\": [\"31916304\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direction opposite to T-cell OXPHOS finding unreconciled\", \"Molecular interaction with OXPHOS machinery unknown\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Per-residue mapping of the 20\\u201344 hydrophobic region and identification of the ER/lipid-droplet sorting hairpin defined the structural determinants of inhibition and localization.\",\n      \"evidence\": \"Systematic mutagenesis with in vitro ATPL lipase assays and fluorescent-construct imaging of ER/LD sorting\",\n      \"pmids\": [\"35026402\", \"36420951\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No high-resolution structure of the G0S2-ATGL complex\", \"How ATGL overrides charge-dependent LD sorting unresolved\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identifying JAZF1 repression of G0S2 via the activator Pur\\u03b2 connected G0S2 to apoptosis control during endometrial decidualization.\",\n      \"evidence\": \"JAZF1 knockdown/overexpression, JAZF1-Pur\\u03b2 Co-IP, promoter analysis, and decidualization/apoptosis assays in hESCs\",\n      \"pmids\": [\"37244968\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which G0S2 drives hESC apoptosis here not detailed\", \"Single tissue context\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"WAT transplantation and LPL epistasis showed that intracellular ATGL activity controlled by G0S2 governs extracellular LPL-mediated plasma triglyceride clearance and atherogenesis.\",\n      \"evidence\": \"G0S2 global KO mice, WAT transplantation rescue, LPL activity measurement, and ATGL inhibitor reversal under dietary lipid challenge\",\n      \"pmids\": [\"40100923\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular link between intracellular lipolysis and LPL stability not defined\", \"Human relevance of the WAT-LPL axis untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The unifying biochemical basis reconciling G0S2's opposing roles in OXPHOS, its non-lipid partners (Bcl-2, nucleolin), and its ATGL-independent functions remains undefined.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structure of any G0S2 complex\", \"Opposing OXPHOS phenotypes across systems unreconciled\", \"E3 ligase for K25 ubiquitination unidentified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [1, 2, 13, 16]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [12]},\n      {\"term_id\": \"GO:0016747\", \"supporting_discovery_ids\": [12]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [0, 4]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [4, 17]},\n      {\"term_id\": \"GO:0005811\", \"supporting_discovery_ids\": [17]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [4, 5]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [4]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [1, 6, 7, 12, 20]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [3, 11, 18]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"PNPLA2\", \"BCL2\", \"NCL\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}